FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890956547> ?p ?o ?g. }

• W2890956547 endingPage "e21000" @default.
• W2890956547 startingPage "e21000" @default.
• W2890956547 abstract "e21000 Background: MCC is a rare skin cancer with a propensity for distant mets, yet the ability of palliative CT to impact survival is unknown. Methods: Pts with MCC were identified from an institutional database from 1990-2015. Demographic and clinical data were abstracted from the medical record. Pts with distant mets were analyzed for survival. Genomic testing by Foundation Medicine, if performed, is reported. Results: 205 pts with MCC were identified; 43 (21%) developed distant mets. Median age was 69 years (range 52-93, 36 male). Median time of follow up was 1.7 years. For initial treatment, 41 pts had surgery and 30 pts had adjuvant radiotherapy. Location of distant mets included: skin (n = 26), liver (n = 17), distant lymph nodes (n = 10),), bone (n = 7) lung (n = 2), heart (n = 2), kidney (n = 1), stomach (n = 1), pancreas (n = 1), and testes (n = 1). Visceral mets were seen in 23 pts. 24 pts received chemotherapy for metastatic disease and 19 did not. CT regimens were platinum/etoposide (n = 21) and doxorubicin, cyclophosphamide, and vincristine (n = 7). At last follow-up, 16 pts were alive and 27 were dead. For the whole cohort, 2-year overall survival (OS) was not increased with the use of CT (41% no CT, 68% with CT; p = 0.222). 2-year OS was 61% for pts without visceral involvement and 49% for pts with visceral mets (p = 0.127). However, 2-year OS of pts with visceral mets who received CT was better than those pts with visceral mets who did not receive CT (77% versus 0%; p = 0.0016). Genomic testing was available for 5 pts. Two pts had no targetable mutations. One pt had a mutation in HRAS G12S. One pt had a PTEN R335 mutation and was treated with temsirolimus but had to stop due to low blood counts after 2 doses so response could not be assessed. One pt had several genomic alterations: CD274 (PD-L1) amplification, JAK2 amplification, KDR G49E, PDCD1LG2 (PD-L2 amplification, and PIK3R2 W165. Conclusions: CT may have a survival benefit in pts with MCC with distant visceral mets. Further genomic testing is needed to inform the role of targeted therapies for pts with metastatic MCC." @default.
• W2890956547 created "2018-09-27" @default.
• W2890956547 creator A5033590445 @default.
• W2890956547 creator A5037908919 @default.
• W2890956547 creator A5062405186 @default.
• W2890956547 creator A5082719040 @default.
• W2890956547 date "2016-05-20" @default.
• W2890956547 modified "2023-09-27" @default.
• W2890956547 title "Benefit of chemotherapy (CT) in patients (pts) with Merkel cell carcinoma (MCC) with distant metastases (mets) and visceral organ involvement." @default.
• W2890956547 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.e21000" @default.
• W2890956547 hasPublicationYear "2016" @default.
• W2890956547 type Work @default.
• W2890956547 sameAs 2890956547 @default.
• W2890956547 citedByCount "2" @default.
• W2890956547 countsByYear W28909565472017 @default.
• W2890956547 countsByYear W28909565472020 @default.
• W2890956547 crossrefType "journal-article" @default.
• W2890956547 hasAuthorship W2890956547A5033590445 @default.
• W2890956547 hasAuthorship W2890956547A5037908919 @default.
• W2890956547 hasAuthorship W2890956547A5062405186 @default.
• W2890956547 hasAuthorship W2890956547A5082719040 @default.
• W2890956547 hasConcept C121608353 @default.
• W2890956547 hasConcept C126322002 @default.
• W2890956547 hasConcept C141071460 @default.
• W2890956547 hasConcept C143998085 @default.
• W2890956547 hasConcept C2776694085 @default.
• W2890956547 hasConcept C2776755627 @default.
• W2890956547 hasConcept C2777546739 @default.
• W2890956547 hasConcept C2778119113 @default.
• W2890956547 hasConcept C2778342957 @default.
• W2890956547 hasConcept C2779429289 @default.
• W2890956547 hasConcept C71924100 @default.
• W2890956547 hasConcept C72563966 @default.
• W2890956547 hasConcept C90924648 @default.
• W2890956547 hasConceptScore W2890956547C121608353 @default.
• W2890956547 hasConceptScore W2890956547C126322002 @default.
• W2890956547 hasConceptScore W2890956547C141071460 @default.
• W2890956547 hasConceptScore W2890956547C143998085 @default.
• W2890956547 hasConceptScore W2890956547C2776694085 @default.
• W2890956547 hasConceptScore W2890956547C2776755627 @default.
• W2890956547 hasConceptScore W2890956547C2777546739 @default.
• W2890956547 hasConceptScore W2890956547C2778119113 @default.
• W2890956547 hasConceptScore W2890956547C2778342957 @default.
• W2890956547 hasConceptScore W2890956547C2779429289 @default.
• W2890956547 hasConceptScore W2890956547C71924100 @default.
• W2890956547 hasConceptScore W2890956547C72563966 @default.
• W2890956547 hasConceptScore W2890956547C90924648 @default.
• W2890956547 hasIssue "15_suppl" @default.
• W2890956547 hasLocation W28909565471 @default.
• W2890956547 hasOpenAccess W2890956547 @default.
• W2890956547 hasPrimaryLocation W28909565471 @default.
• W2890956547 hasRelatedWork W2027086316 @default.
• W2890956547 hasRelatedWork W2047930003 @default.
• W2890956547 hasRelatedWork W2092140577 @default.
• W2890956547 hasRelatedWork W2121694206 @default.
• W2890956547 hasRelatedWork W2252336101 @default.
• W2890956547 hasRelatedWork W2401224456 @default.
• W2890956547 hasRelatedWork W2412181118 @default.
• W2890956547 hasRelatedWork W2414338140 @default.
• W2890956547 hasRelatedWork W2416766314 @default.
• W2890956547 hasRelatedWork W2886757491 @default.
• W2890956547 hasVolume "34" @default.
• W2890956547 isParatext "false" @default.
• W2890956547 isRetracted "false" @default.
• W2890956547 magId "2890956547" @default.
• W2890956547 workType "article" @default.